Transgene

Report Publication Announcement • Dec 22, 2016

Transgene Announces Upcoming Investor Events

Strasbourg, France, December 22, 2016, 6:00 pm CET – Transgene today announced that management will participate in the upcoming investor events set out below.

• Oddo Forum: January 5 & 6, 2017 Lyon, France
• Biotech Showcase (concurrent with the J.P. Morgan 35th Healthcare Conference): January 9 to 11, 2017 - San Francisco, USA
• Biomed Event: January 26, 2017 Paris, France
• Lond Capital Mid Small Cap Forum: February 1 & 2, 2017 Zurich, Switzerland
• Exane BNP Paribas 19th Healthcare Conference: March 13 & 14, 2017 Paris, France

Next scheduled financial communication

Financial results for 2016 and business update March 20, 2017 after market close

Contacts

Transgene:

Media contacts:

Lucie Larguier Director Corporate Communications & IR +33 (0)3 88 27 91 04 investorrelations@transgene.fr

Citigate Dewe Rogerson David Dible / Marine Perrier + 44 (0)20 7638 9571 transgene@citigatedr.co.uk

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs, including TG4001, in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA